标题
The Emerging Roles of Rad51 in Cancer and Its Potential as a Therapeutic Target
作者
关键词
-
出版物
Frontiers in Oncology
Volume 12, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2022-07-07
DOI
10.3389/fonc.2022.935593
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- BMI1 nuclear location is critical for RAD51-dependent response to replication stress and drives chemoresistance in breast cancer stem cells
- (2022) Violette Azzoni et al. Cell Death & Disease
- RADX controls RAD51 filament dynamics to regulate replication fork stability
- (2021) Madison B. Adolph et al. MOLECULAR CELL
- Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancer
- (2021) Michal M Hoppe et al. EMBO Molecular Medicine
- Homologous Recombination Repair Deficiency and Implications for Tumor Immunogenicity
- (2021) Sandra van Wilpe et al. Cancers
- Association of RAD51 with Homologous Recombination Deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial
- (2021) A. Llop-Guevara et al. ANNALS OF ONCOLOGY
- RADX prevents genome instability by confining replication fork reversal to stalled forks
- (2021) Archana Krishnamoorthy et al. MOLECULAR CELL
- Molecular Determinant of DIDS Analogs Targeting RAD51 Activity
- (2021) Denis Velic et al. MOLECULES
- New RAD51 Inhibitors to Target Homologous Recombination in Human Cells
- (2021) Irina S. Shkundina et al. Genes
- Regulation of RAD51 at the Transcriptional and Functional Levels: What Prospects for Cancer Therapy?
- (2021) Esin Orhan et al. Cancers
- Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts
- (2021) F. Guffanti et al. BRITISH JOURNAL OF CANCER
- EGFR-mediated Rad51 expression potentiates intrinsic resistance in prostate cancer via EMT and DNA repair pathways
- (2021) Mohit Rajput et al. LIFE SCIENCES
- Nucleolar and spindle associated protein 1 enhances chemoresistance through DNA damage repair pathway in chronic lymphocytic leukemia by binding with RAD51
- (2021) Yang Han et al. Cell Death & Disease
- CTBP1 strengthens the cisplatin resistance of gastric cancer cells by upregulating RAD51 expression
- (2021) Yuluo Wu et al. Oncology Letters
- Expression Levels of RAD51 Inversely Correlate with Survival of Glioblastoma Patients
- (2021) Christopher Morrison et al. Cancers
- Overexpression of HMGA1 confers radioresistance by transactivating RAD51 in cholangiocarcinoma
- (2021) Jianping Song et al. Cell Death Discovery
- CtBP1 transactivates RAD51 and confers cisplatin resistance to breast cancer cells
- (2020) Yu Deng et al. MOLECULAR CARCINOGENESIS
- Role of Rad51 and DNA repair in cancer: A molecular perspective
- (2020) Erik Laurini et al. PHARMACOLOGY & THERAPEUTICS
- Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer
- (2020) Neha Chopra et al. Nature Communications
- RAD51 Gene Family Structure and Function
- (2020) Braulio Bonilla et al. Annual Review of Genetics
- Mitochondrial superoxide contributes to oxidative stress exacerbated by DNA damage response in RAD51-depleted ovarian cancer cells
- (2020) Limei Xu et al. Redox Biology
- NELF complex fosters BRCA1 and RAD51 recruitment to DNA damage sites and modulates sensitivity to PARP inhibition
- (2020) Laila A. Bishara et al. DNA REPAIR
- DNA Repair Protein Rad51 Induces Tumor Growth and Metastasis in Esophageal Squamous Cell Carcinoma via a p38/Akt-Dependent Pathway
- (2019) Wen-Chin Chiu et al. ANNALS OF SURGICAL ONCOLOGY
- PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells
- (2019) Sylvie M. Noordermeer et al. TRENDS IN CELL BIOLOGY
- RAD51 is a potential marker for prognosis and regulates cell proliferation in pancreatic cancer
- (2019) Xiaomeng Zhang et al. Cancer Cell International
- RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
- (2018) C Cruz et al. ANNALS OF ONCOLOGY
- Epithelial Mesenchymal Transition in Tumor Metastasis
- (2018) Vivek Mittal Annual Review of Pathology-Mechanisms of Disease
- BRCA1/2 testing: therapeutic implications for breast cancer management
- (2018) Nadine M. Tung et al. BRITISH JOURNAL OF CANCER
- Biomarkers for Homologous Recombination Deficiency in Cancer
- (2018) Michal M Hoppe et al. JNCI-Journal of the National Cancer Institute
- A Short BRCA2-Derived Cell-Penetrating Peptide Targets RAD51 Function and Confers Hypersensitivity toward PARP Inhibition
- (2018) Anika Trenner et al. MOLECULAR CANCER THERAPEUTICS
- Chromosomal instability drives metastasis through a cytosolic DNA response
- (2018) Samuel F. Bakhoum et al. NATURE
- RADX Modulates RAD51 Activity to Control Replication Fork Protection
- (2018) Kamakoti P. Bhat et al. Cell Reports
- Biomarkers for Homologous Recombination Deficiency in Cancer
- (2018) Michal M Hoppe et al. JNCI-Journal of the National Cancer Institute
- Enhancing the efficacy of glycolytic blockade in cancer cells via RAD51 inhibition
- (2018) John J. Wilson et al. CANCER BIOLOGY & THERAPY
- Jab1/Cops5 contributes to chemoresistance in breast cancer by regulating Rad51
- (2018) Guohong Liu et al. CELLULAR SIGNALLING
- A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
- (2018) Marta Castroviejo‐Bermejo et al. EMBO Molecular Medicine
- The F-Box Domain-Dependent Activity of EMI1 Regulates PARPi Sensitivity in Triple-Negative Breast Cancers
- (2018) Antonio Marzio et al. MOLECULAR CELL
- New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer
- (2018) Anushka Dongre et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- ATM-dependent activation of SIM2s regulates homologous recombination and epithelial–mesenchymal transition
- (2018) Scott J. Pearson et al. ONCOGENE
- ROS and the DNA damage response in cancer
- (2018) Upadhyayula Sai Srinivas et al. Redox Biology
- Upregulation of RAD51 expression is associated with progression of thyroid carcinoma
- (2017) R. Sarwar et al. EXPERIMENTAL AND MOLECULAR PATHOLOGY
- LncRNA lnc-RI regulates homologous recombination repair of DNA double-strand breaks by stabilizing RAD51 mRNA as a competitive endogenous RNA
- (2017) Liping Shen et al. NUCLEIC ACIDS RESEARCH
- RAD51 Is a Selective DNA Repair Target to Radiosensitize Glioma Stem Cells
- (2017) Harry O. King et al. Stem Cell Reports
- HDAC Inhibition Induces MicroRNA-182, which Targets RAD51 and Impairs HR Repair to Sensitize Cells to Sapacitabine in Acute Myelogenous Leukemia
- (2016) T.-H. Lai et al. CLINICAL CANCER RESEARCH
- RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer
- (2016) Yajing Liu et al. CLINICAL CANCER RESEARCH
- Homologous recombination deficiency and ovarian cancer
- (2016) Jonathan A. Ledermann et al. EUROPEAN JOURNAL OF CANCER
- A phosphorylation–deubiquitination cascade regulates the BRCA2–RAD51 axis in homologous recombination
- (2016) Kuntian Luo et al. GENES & DEVELOPMENT
- Targeting DNA Repair in Cancer: Beyond PARP Inhibitors
- (2016) Jessica S. Brown et al. Cancer Discovery
- Targeting the DNA Damage Response in Cancer
- (2015) Mark J. O’Connor MOLECULAR CELL
- Cyclin D1 promotes BRCA2-Rad51 interaction by restricting cyclin A/B-dependent BRCA2 phosphorylation
- (2015) C Chalermrujinanant et al. ONCOGENE
- Protective role of miR-155 in breast cancer through RAD51 targeting impairs homologous recombination after irradiation
- (2014) P. Gasparini et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Rad51 Expression Is a Useful Predictive Factor for the Efficacy of Neoadjuvant Chemoradiotherapy in Squamous Cell Carcinoma of the Esophagus
- (2013) Tomonori Nakanoko et al. ANNALS OF SURGICAL ONCOLOGY
- A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia
- (2013) Jiewen Zhu et al. EMBO Molecular Medicine
- Tumor glycolysis as a target for cancer therapy: progress and prospects
- (2013) Shanmugasundaram Ganapathy-Kanniappan et al. Molecular Cancer
- MiR-96 Downregulates REV1 and RAD51 to Promote Cellular Sensitivity to Cisplatin and PARP Inhibition
- (2012) Yemin Wang et al. CANCER RESEARCH
- Rad51 Promoter-Targeted Gene Therapy Is Effective for In Vivo Visualization and Treatment of Cancer
- (2011) Christopher M Hine et al. MOLECULAR THERAPY
- DIDS, a chemical compound that inhibits RAD51-mediated homologous pairing and strand exchange
- (2009) Takako Ishida et al. NUCLEIC ACIDS RESEARCH
- The checkpoint kinases Chk1 and Chk2 regulate the functional associations between hBRCA2 and Rad51 in response to DNA damage
- (2008) E M Bahassi et al. ONCOGENE
- Use of the Rad51 promoter for targeted anti-cancer therapy
- (2008) C. M. Hine et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now